MMS22L

Across TCGA pan-cancer cohorts, MMS22L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MMS22L data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MMS22L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MMS22L expression acts as an unfavorable survival marker.

HNSC, GBM, and PDAC are the cancer types where MMS22L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.904	1.000	.028	15	view →
GBM	DFS	Tertile	All	0.193	0.567	.024	6	view →
PDAC	OS	Median	II,III,IV	0.189	0.619	.038	3	view →
LUAD	OS	Quartile	All	0.719	1.000	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MMS22L–HNSC (DFS)

Open the HNSC breakdown →